Akin Atmaca

6.2k total citations · 2 hit papers
61 papers, 3.3k citations indexed

About

Akin Atmaca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Akin Atmaca has authored 61 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Akin Atmaca's work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Akin Atmaca is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Akin Atmaca collaborates with scholars based in Germany, United States and Switzerland. Akin Atmaca's co-authors include Elke Jäger, Alexander Knuth, Salah‐Eddin Al‐Batran, Claudia Pauligk, Matthew D. Hellmann, Scott Antonia, Emiliano Calvo, Paolo A. Ascierto, Margaret K. Callahan and G. Seipelt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.

In The Last Decade

Akin Atmaca

54 papers receiving 3.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

2018 670 citations Matthew D. Hellmann, Margaret K. Callahan et al. Cancer Cell profile →
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

2008 568 citations Salah‐Eddin Al‐Batran, J. T. Hartmann et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Akin Atmaca	2.2k	1.4k	845	580	565	61	3.3k
Geoffrey Y. Ku	2.2k 1.0×	1.4k 1.0×	559 0.7×	181 0.3×	1.0k 1.9×	170	3.4k
Feng‐Hua Wang	1.5k 0.7×	861 0.6×	872 1.0×	256 0.4×	637 1.1×	126	2.9k
Atsuo Takashima	1.7k 0.8×	1.5k 1.1×	388 0.5×	218 0.4×	923 1.6×	222	2.9k
Zhi Peng	1.3k 0.6×	669 0.5×	481 0.6×	223 0.4×	434 0.8×	106	2.1k
Young Soo Park	1.2k 0.5×	1.9k 1.4×	546 0.6×	298 0.5×	1.1k 2.0×	160	3.2k
Philippe Tanière	1.1k 0.5×	824 0.6×	1.0k 1.2×	238 0.4×	618 1.1×	94	2.6k
Jerome C. Landry	1.8k 0.8×	1.3k 0.9×	516 0.6×	378 0.7×	1.5k 2.6×	115	3.3k
Yoshitaka Honma	952 0.4×	776 0.5×	878 1.0×	202 0.3×	591 1.0×	170	2.3k
Tatsuya Yoshida	1.3k 0.6×	1.3k 0.9×	469 0.6×	222 0.4×	556 1.0×	168	2.5k
Minoru Kitago	1.9k 0.9×	719 0.5×	1.1k 1.3×	459 0.8×	1.1k 2.0×	191	3.8k

Countries citing papers authored by Akin Atmaca

Since Specialization

Citations

This map shows the geographic impact of Akin Atmaca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akin Atmaca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akin Atmaca more than expected).

Fields of papers citing papers by Akin Atmaca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akin Atmaca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akin Atmaca. The network helps show where Akin Atmaca may publish in the future.

Co-authorship network of co-authors of Akin Atmaca

This figure shows the co-authorship network connecting the top 25 collaborators of Akin Atmaca. A scholar is included among the top collaborators of Akin Atmaca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akin Atmaca. Akin Atmaca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arruda, Lucas C. M., et al.. (2025). Multiple infusions of TILs expanded with IL-2/IL-15/IL-21 lead to an improved PK/PD profile and long-term clinical responses in patients with cold tumors. Cytotherapy. 27(5). S165–S165.

Atmaca, Akin, Alex Stein, Daniel Pink, et al.. (2025). 1857P Eftilagimod alpha (soluble LAG-3 protein) combined with first-line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC): Updates from INSIGHT-003 (IKF614). Annals of Oncology. 36. S1000–S1000.

Arruda, Lucas C. M., et al.. (2025). Tumor-infiltrating lymphocytes-derived CD8 ⁺ clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma. OncoImmunology. 14(1). 2559784–2559784.

Atmaca, Akin, et al.. (2023). 1042P INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas. Annals of Oncology. 34. S632–S632. 2 indexed citations

Al-Batran, S-E., Daniel Mueller, Akin Atmaca, et al.. (2023). A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology. ESMO Open. 8(5). 101623–101623. 5 indexed citations

Karbach, Julia, et al.. (2023). Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer. Journal for ImmunoTherapy of Cancer. 11(1). e005847–e005847. 9 indexed citations

Bozorgmehr, Farastuk, J.R. Fischer, Marc Bischof, et al.. (2020). LBA58 ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial. Annals of Oncology. 31. S1187–S1187. 7 indexed citations

Hellmann, Matthew D., Margaret K. Callahan, Mark M. Awad, et al.. (2018). Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 33(5). 853–861.e4. 670 indexed citations breakdown →

Karbach, Julia, Sacha Gnjatic, Akin Atmaca, et al.. (2014). Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. Cancer Immunology Research. 2(5). 404–409. 12 indexed citations

10.

Brueckl, Wolfgang M., Salah‐Eddin Al‐Batran, Joachim H. Ficker, et al.. (2013). Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. International Journal of Cancer. 133(8). 1825–1831. 21 indexed citations

11.

Marinis, Filippo de, Akin Atmaca, Marcello Tiseo, et al.. (2013). A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(8). 1091–1094. 41 indexed citations

12.

Atmaca, Akin, Dominique Werner, Claudia Pauligk, et al.. (2012). The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer. 12(1). 524–524. 43 indexed citations

13.

Weidmann, Eckhart, Antje Neumann, F. Fauth, et al.. (2011). Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Annals of Oncology. 22(8). 1839–1844. 65 indexed citations

14.

Al‐Batran, Salah‐Eddin, Claudia Pauligk, Dominique Werner, et al.. (2011). The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Annals of Oncology. 23(7). 1699–1705. 23 indexed citations

15.

Karbach, Julia, Antje Neumann, Akin Atmaca, et al.. (2010). Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients. Clinical Cancer Research. 17(4). 861–870. 63 indexed citations

16.

Wedel, Steffen, Anna Sparatore, Piero Del Soldato, et al.. (2008). New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. Journal of Cellular and Molecular Medicine. 12(6a). 2457–2466. 31 indexed citations

17.

Al‐Batran, Salah‐Eddin, H.G. Meerpohl, Gϋnter von Minckwitz, et al.. (2006). Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m<sup>2</sup> Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer. Oncology. 70(2). 141–146. 44 indexed citations

18.

Al-Batran, Salah-Eddin, Joachim Bischoff, Gϋnter von Minckwitz, et al.. (2006). The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. British Journal of Cancer. 94(11). 1615–1620. 59 indexed citations

19.

Minckwitz, Gϋnter von, Sebastian Harder, Elke Jäger, et al.. (2005). Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Research. 7(5). R617–26. 75 indexed citations

20.

Jäger, Elke, Julia Karbach, Sacha Gnjatic, et al.. (2002). Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. PubMed. 2. 12–12. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact